A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers: Quetiapine for marijuana withdrawal
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Marijuana withdrawal contributes to the high relapse rates in individuals seeking treatment for marijuana-use disorders. Quetiapine, an atypical antipsychotic, reduces characteristic symptoms of marijuana withdrawal in a variety of psychiatric conditions, including mood lability, sleep disruption and anorexia. This human laboratory study investigated the effectiveness of quetiapine to decrease marijuana withdrawal and relapse to marijuana use in non-treatment-seeking marijuana smokers. Volunteers were maintained on placebo or quetiapine (200 mg/day) in this double-blind, counter-balanced, within-subject study consisting of two 15-day medication phases, the last 8 days of which were in-patient. On the first in-patient day, active marijuana [6.2% delta (9)-tetrahydrocannabinol (THC)] was repeatedly smoked under controlled conditions. For the next 3 days, inactive marijuana (0.0% THC) was available for self-administration (withdrawal). On the subsequent 4 days, active marijuana (6.2% THC) was available for self-administration (relapse). Volunteers (n = 14) who smoked an average of 10 marijuana cigarettes/day, 7 days/week, completed the study. Under placebo, withdrawal was marked by increased subjective ratings of negative mood, decreased sleep quality, and decreased caloric intake and weight loss. Compared with placebo, quetiapine improved sleep quality, increased caloric intake and decreased weight loss. However, quetiapine increased marijuana craving and marijuana self-administration during the relapse phase. These data do not suggest that quetiapine shows promise as a potential treatment for marijuana dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Marijuana Use Disorders in the United States: 1991-1992 and 2001-2002
Compton, W. M., Grant, B. F., Colliver, J. D., Glantz, M. D., & Stinson, F. S. (2004) · JAMA · doi:10.1001/jama.291.17.2114 · Cited by 537
Mehmedic, Z., Chandra, S., Slade, D., Denham, H., Foster, S., Patel, A. S., Ross, S. A., Khan, I. A., & ElSohly, M. A. (2010) · Journal of Forensic Sciences · doi:10.1111/j.1556-4029.2010.01441.x · Cited by 475
A randomized controlled trial of brief cognitive–behavioral interventions for cannabis use disorder
Copeland, J., Swift, W., Roffman, R., & Stephens, R. (2001) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(01)00179-9 · Cited by 322 · cited 1×
“Although these therapies have shown some promise for decreasing marijuana use, maintaining abstinence proves to be a challenge (Stephens, Roffman & Simpson 1994; Copeland et al. 2001; Carroll et al. 2006; Stanger et al. 2009; Ramchand et al. 2011).”
BackgroundControversies in translational research: drug self-administration.
Haney, M., & Spealman, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1079-x · Cited by 270 · cited 1×
“…effectiveness of a medication to treat substance use disorders is best predicted by its ability to decrease selfadministration in the laboratory (Comer et al., 2008; Haney & Spealman 2008), the current findings suggest that quetiapine does not show promise for the treatment of marijuana dependence.”
BackgroundSelf-citationLevin, F. R., Mariani, J. J., Brooks, D. J., Pavlicova, M., Cheng, W., & Nunes, E. V. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.12.010 · Cited by 232 · cited 2×
“Recently, the predictive validity of the laboratory relapse model was supported with a clinical trial examining dronabinol for treating marijuana dependence (Levin et al. 2011).”
BackgroundResultCarroll, K. M., Easton, C. J., Nich, C., Hunkele, K. A., Neavins, T. M., Sinha, R., Ford, H. L., Vitolo, S. A., Doebrick, C. A., & Rounsaville, B. J. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.74.5.955 · Cited by 214
Cited by
Angarita, G. A., Emadi, N., Hodges, S., & Morgan, P. T. (2016) · Addiction Science & Clinical Practice · doi:10.1186/s13722-016-0056-7 · Cited by 358
The cannabis withdrawal syndrome: current insights
Bonnet, U., & Preuss, U. (2017) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s109576 · Cited by 221
“Quetiapine (200 mg/day) improved appetite and sleep quality during the CWS but worsened marijuana craving and drove selfadministration of marijuana.(95) A more recent open pilot study reported a decrease of cannabis use within 8 weeks of quetiapine treatment (25–600 mg).”
Treatment of Cannabis Use Disorder: Current Science and Future Outlook
Sherman, B. J., & McRae‐Clark, A. L. (2016) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1747 · Cited by 208
“Quetiapine, an atypical antipsychotic, improved sleep quality and appetite during cannabis withdrawal but increased cannabis craving and relapse.(58) As discussed earlier, lofexidine did not demonstrate utility on its own for cannabis withdrawal; however, the combination of lofexidine and oral THC significantly amelio…”
BackgroundPharmacotherapies for cannabis dependence.
Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub2 · Cited by 156
Pharmacotherapies for cannabis dependence
Nielsen, S., Gowing, L., Sabioni, P., & Le Foll, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub3 · Cited by 96
Metadata
- Authors
- Cooper, Z. D., Foltin, R. W., Hart, C. L., Vosburg, S. K., Comer, S. D., & Haney, M.
- Venue
- Addiction Biology
- Publisher
- Wiley
- Published
- 2012-06-28
- Volume
- 18
- Issue
- 6
- Pages
- 993-1002
- ISSN
- 1355-6215 (ISSN-L)
- OpenAlex
- W1912126448
- Cited by
- 63
- References
- 6
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers: Quetiapine for marijuana withdrawal. https://app.cochat.ai/papers/10.1111/j.1369-1600.2012.00461.x
- The paper
- Cooper, Z. D., Foltin, R. W., Hart, C. L., Vosburg, S. K., Comer, S. D., & Haney, M. (2013). A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers: Quetiapine for marijuana withdrawal. Addiction Biology. https://doi.org/10.1111/j.1369-1600.2012.00461.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.